Market Insight - Differentiation guiding firms through maze of hepatitis C drug development
This article was originally published in Scrip
The therapeutic landscape in HCV treatment is at an inflection point – recent data from the first generation of protease inhibitors promise the dawn of a new standard of care. But do not expect to see a "winner takes all" market, say Paul Zhang, Dr Behrad Derakhshan and Dr David Muccino. Instead, individualised therapy will allow clinicians to tailor HCV management based on patient profiles and viral response.